BARDA Archives - Page 2 of 3 - EverGlade

BARDA

BARDA RAPID RFI antibodies

BARDA’s RAPID RFI for Next-Generation Antibody Design through Production

Leave a Comment / BARDA, Life Sciences / By

BARDA RAPID RFI RAPID Overview The Biomedical Advanced Research and Development Authority (BARDA) has issued a new Request for Information (RFI) titled “Rapid Antibody Production for Immunoassay Diagnostics (RAPID)”. Through this RFI, BARDA seeks to more deeply understand causes of existing bottlenecks in the antibody generation process (design through production) and assess the R&D landscape […]

BARDA’s RAPID RFI for Next-Generation Antibody Design through Production Read More »

BARDA advancing pathogen agnostic diagnostics

Advancing Pathogen-Agnostic Diagnostics

Leave a Comment / BARDA, Life Sciences / By

BARDA RRPV-26-09-AgDx Request for Project Proposals The Biomedical Advanced Research and Development Authority (BARDA) has released a new Request for Project Proposals (RPP-26-09-AgDx) through the Rapid Response Partnership Vehicle (RRPV), seeking to revolutionize the nation’s diagnostic readiness for infectious disease threats. Managed by Advanced Technology International (ATI), the RRPV enables collaboration between industry, academia, and

Advancing Pathogen-Agnostic Diagnostics Read More »

BARDA’s RPP to Onshore Vaccine Manufacturing for Viral Hemorrhagic Fevers

Leave a Comment / BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has issued a new Request for Project Proposals (RPP-26-10-VHF) under its Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). This solicitation represents a key step in building domestic capacity for advanced vaccine manufacturing to strengthen the nation’s biosecurity infrastructure.

BARDA’s RPP to Onshore Vaccine Manufacturing for Viral Hemorrhagic Fevers Read More »

HHS Operations During A Government Shutdown

Leave a Comment / Life Sciences / By

When the federal government faces a lapse in appropriations, agencies across the Department of Health and Human Services (HHS) must implement contingency plans to sustain critical activities. Both the Advanced Research Projects Agency for Health (ARPA-H) and the Administration for Strategic Preparedness and Response (ASPR), which houses the Biomedical Advanced Research and Development Authority (BARDA),

HHS Operations During A Government Shutdown Read More »

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies

Leave a Comment / BARDA, Life Sciences / By

Driving Innovation in Antibody Manufacturing The Biomedical Advanced Research and Development Authority (BARDA) has launched a new Request for Project Proposals (RPP) aimed at transforming the speed, efficiency, and resilience of antibody (Ab) production. Issued under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), the initiative seeks to integrate advanced manufacturing technologies into Ab production systems to

BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies Read More »

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates

Leave a Comment / BARDA, Life Sciences / By

As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

Leave a Comment / All Posts, BARDA, Life Sciences / By

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

antiviral therapeutics against filoviruses

New Opportunities with DRIVe: ReBooT and RePAIR Amendments

Leave a Comment / All Posts, BARDA, Life Sciences / By

Amendment 034 – DRIVe EZ BAA_ReBooT_RePAIR New Opportunities with DRIVe: ReBooT and RePAIR Amendments The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the

New Opportunities with DRIVe: ReBooT and RePAIR Amendments Read More »

PAHPA program funding

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness

Leave a Comment / All Posts, BARDA, Life Sciences / By

Congress’s passage of a continuing resolution (CR) has averted a shutdown and provided temporary relief until late March. However, this short-term fix exposes significant gaps in public health and technology preparedness that demand immediate attention. As critical programs approach expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers have a

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

Leave a Comment / All Posts, BARDA, Life Sciences / By

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

Leave a Comment / All Posts, BARDA, Life Sciences / By

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

monoclonal antibody

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis

Leave a Comment / All Posts, BARDA, Life Sciences / By

PrEP_Solicitation_Monoclonal_Antibody_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of monoclonal antibody (mAb) platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The solicitation focuses on advancing the development of mAb

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis Read More »

Scroll to Top